Effect of activated recombinant factor VII versus tranexamic acid infusion on bleeding during spine surgery, randomized, controlled, double blinded trial  by ELShamaa, Hossam A. & ELokda, Sherif A.
Egyptian Journal of Anaesthesia (2015) 31, 149–153HO ST E D  BY
Egyptian Society of Anesthesiologists
Egyptian Journal of Anaesthesia
www.elsevier.com/locate/egja
www.sciencedirect.comResearch ArticleEﬀect of activated recombinant factor VII versus
tranexamic acid infusion on bleeding during spine
surgery, randomized, controlled, double blinded trial* Corresponding author at: Erfan & Bagedo General Hospital, King
Fahad St. Alfaisaleya, P.O Box 6519 Jeddah 2452, Saudi Arabia. Tel.:
+966500984921.
Peer review under responsibility of Egyptian Society of Anesthesiol-
ogists.
http://dx.doi.org/10.1016/j.egja.2014.12.009
1110-1849 ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.Hossam A. ELShamaa a,*, Sherif A. ELokda ba Anesthesia Department, Faculty of Medicine, Cairo University, Egypt
b Anesthesia Department, Faculty of Medicine, Ain Shams University, Egypt
Received 7 November 2014; revised 15 December 2014; accepted 23 December 2014
Available online 7 February 2015KEYWORDS
Tranexamic acid;
Recombinant factor VII;
Spine;
BleedingAbstract Background: Antiﬁbrinolytic drugs, such as tranexamic acid are medications that facil-
itate hemostasis and decrease blood loss and the need for blood transfusion during major surgery.
Activated recombinant coagulation factor VII is a novel hemostatic agent, studies revealed that it is
helpful hemostatic in disorders with impaired hemostasis, as well as in patients with normal hemo-
static function to minimize perioperative blood loss. This study aimed to compare the efﬁcacy of
activated recombinant factor VII with tranexamic acid in reducing the perioperative blood loss.
Methods: 50 patients undergoing spine surgery were enrolled in this study. Group A patients were
given activated recombinant factor VII and group T patients given tranexamic acid. In both groups,
anesthesia was induced using fentanyl 3 lg/kg and propofol 2 mg/kg; muscle relaxation was initi-
ated using cisatracurium 0.2 mg/kg. Transfusion of blood and its products was done according
to a value guide. The primary outcome variable of the study was the total volume of blood loss
in the perioperative period. Secondary outcome variables include perioperative transfusion require-
ment, and the number of patients who needed transfusion, as well as time of operation. A P-value
less than 0.05 is considered statistically signiﬁcant.
Results: The current study showed that the total perioperative blood loss in groupAwas signiﬁcantly
lower than group T. None of the patients required ICU admission, as well as reentry to operating the-
ater. Furthermore, no signiﬁcant difference was detected in the number of patients needed blood
transfusion. Intraoperative bleeding was associated with a slight decrease of hemoglobin in group A.
Conclusion: The present study concluded that administration of activated recombinant factor VII in
spine surgery reduces the total perioperative blood loss and the total volume of intraoperative blood
transfusion compared with tranexamic acid, with no evidence of adverse effects.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
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Antiﬁbrinolytic drugs, such as tranexamic acid and aprotinin,
are easily accessible medications that facilitate hemostasis and
decrease blood loss and the need for allogenic blood transfu-
sion during major surgery. Their efﬁcacy has been evaluated
in different types of surgical operations as orthopedic, cardio-
vascular and hepatic operations [1,2]. Tranexamic acid is a well
known pharmacological agent; it is a simple and inexpensive
agent that interferes with the process of ﬁbrinolysis thus
decrease blood loss and the risk of blood transfusion during
surgery [3,4]. It produces its action by blocking the lysine bind-
ing site of plasminogen preventing its conversion to plasmin on
the surface of ﬁbrin inhibiting ﬁbrinolysis and thus reducing
the intra and postoperative blood loss, so becoming commonly
used in orthopedic surgery [5].
Activated recombinant coagulation factor VII is a recently
used novel hemostatic agent. Many bleeding disorders are
managed nowadays using it, including congenital hemophilia
with inhibitors, congenital factor VII deﬁciency, acquired
hemophilia as well as thrombocytopenia, furthermore, studies
revealed that activated recombinant factor VII is also helpful
as a hemostatic in some other disorders associated with
impaired hemostasis. However, other studies evaluated the
efﬁcacy of activated recombinant factor VII in patients with
normal hemostatic function to minimize perioperative blood
loss during orthopedic surgery [6,7].
Spine surgeries may vary from simple to complex e.g. spinal
ﬁxation and scoliosis surgery and may vary also in the antici-
pated blood loss. Multiple factors make this surgery poten-
tially associated with moderate to major bleeding that
usually necessitates blood transfusion, that is why multiple
measures are used to decrease the possibility of transfusion
as hypotensive anesthesia [8]. Increased concerns about the
risks of transfusion including acquired infections, anaphylaxis,
transfusion related acute lung injury (TRALI) and hemolytic
reaction, in addition to immune modulation effects of allogen-
ic blood that may increase infection rates aroused the impor-
tance of investigating using the various hemostatic agents
such as recombinant activated factor VII of the coagulation
factors and antiﬁbrinolytic drugs e.g. tranexamic acid to min-
imize the blood loss during this surgery [9].
The aim of this randomized, controlled, double-blinded
study was to compare the efﬁcacy of activated recombinant
factor VII with tranexamic acid in reducing the perioperative
blood loss as well as the possibility of blood transfusion in
patients undergoing spine surgery, and to assess their safety
as regard causing postoperative thrombo-embolic
complications.
2. Patients and methods
After obtaining approval from the Clinical Research Ethics
Committee of Erfan and Bagedo General hospital and obtain-
ing informed consent. 50 patients aged (18–65 years), ASA
physical status I, II & III, undergoing spine surgery (three level
spinal fusion or scoliosis) were enrolled in this study. The
patients were randomly divided, using concealed envelope
method, into 2 equal groups: Group A patients (n= 25) were
given Activated recombinant factor VII and group T patients
(n= 25) given tranexamic acid. Exclusion criteria include:patients outside the age range, history of thrombo-embolic
event e.g. pulmonary embolism, deep venous thrombosis, trau-
matic spine injury, morbid obesity (weight > 125 kg), known
congenital bleeding disorder, known allergy to the used drugs
and known pregnant or lactating patients. Inclusion criteria
were the ability to consent, and absence of renal and hepatic
diseases.
All patients were premedicated with 5 mg midazolam I.M.
30 min before shifting to OR. After OR admission, the stan-
dard monitors including noninvasive arterial blood pressure,
electrocardiography and pulse oximetry were applied. A 20
gauge intravenous catheter was inserted and 4 mg ondansetron
IV was given. 22 gauge arterial catheter was inserted before
induction of anesthesia and invasive blood pressure was mon-
itored. In both groups, anesthesia was induced using fentanyl
3 lg/kg and propofol (Deprivan) 2 mg/kg; muscle relaxation
was initiated using cisatracurium (Nimbex) 0.2 mg/kg. Then
patients were intubated after 3 min of face mask ventilation
using endotracheal tube of appropriate size via direct laryngos-
copy, with lidocaine 1 mg/kg IV given before intubation to
minimize stress response. Anesthesia was maintained by 2%
sevoﬂurane with 50% nitrous oxide in oxygen.
In group A, activated recombinant factor VII (NovoSev-
en, Novo Nordisk A/S, 2880 Bagsvaerd, Denmark) 100 lg/
kg in 50 ml normal saline was administered IV before skin inci-
sion, followed by intravenous infusion of normal saline as a
placebo as simulation of tranexamic acid infusion in group
T. while in group T, tranexamic acid (cyklokapron, Pﬁzer Can-
ada Inc, Kirkland, Quebec, H9J 2M5) 100 mg/kg in 50 ml nor-
mal saline was infused IV before skin incision, followed by
intravenous infusion of tranexamic acid at rate of 1 mg/kg/h.
Infusions in both groups were discontinued after closure of
skin incision. Intravenous solutions were prepared in the phar-
macy outside the operating theatre and sent to the anesthesiol-
ogist as apparently identical drip with a predetermined rate
depending on the patient body weight. Transfusion of blood
and its products was done according to a value guide; where
packed RBC is transfused if hemoglobin level is less than
10 g/dl, fresh frozen plasma (FFP) is given if prothrombin time
(PT), activated partial thromboplastin time (aPTT) and inter-
national normalized ratio (INR) become 1.5 the normal preop-
erative value, platelet was transfused if its count is less than
100,000/cmm. During surgery coagulation parameters were
tested every hour.
The primary outcome variable of the study was the total
volume of blood loss in the perioperative period, which is con-
sidered as the time from the start of surgery (skin incision) till
the end of the ﬁrst 24 h postoperatively. This volume was cal-
culated as the sum of the blood collected in the suction device,
the drapes and swabs after being weighed postoperatively and
the total volume of blood in the drains, after subtracting the
ﬂuid volume used for irrigation intraoperatively as the tech-
nique described by Jansen et al. [10]. Secondary outcome vari-
ables were perioperative transfusion requirement (total volume
transfused of blood and its component), and the number of
patients who needed transfusion, duration of operation (from
skin incision till skin closure), total amount of IV ﬂuids used
both colloids (6% hydroxyethyl starch 130/0.4 ‘‘Voluven,
Fresenius Kabi, Humborg, Germany’’) and crystalloids (lac-
tated ringers solution), number of patients who needed ICU
admission, in addition to the change in the value of the coag-
ulation parameters (PT, aPTT, INR) or hemoglobin level (Hb)
Table 1 Demographic and operative data. Values are
expressed as mean ± SD.
Group A Group T
(n= 25) (n= 25)
Age (year) 41.6 ± 3.3 43.4 ± 3.9
Gender (M/F) 19/6 17/8
Body weight (kg) 80 ± 30 76 ± 28
Height (cm) 169 ± 5 174 ± 3
Duration of surgery (min) 269 ± 25 273 ± 29
Type of surgery
Multiple level spinal fusion 16 (64%) 18 (72%)
Scoliosis correction 2 (8%) 1 (4%)
Spinal canal stenosis 7 (28%) 6 (24%)
No signiﬁcant differences between the two groups. (P
value > 0.05).
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Figure 2 The primary (blood loss) and secondary (transfusion
requirement) outcome variables. * indicates signiﬁcant difference.
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immediately postoperatively and after 24 h, and ﬁnally the
incidence of complications including severe postoperative
bleeding or thrombo-embolic events as DVT, pulmonary
embolism, and stroke.
Data were analyzed using computer statistical software sys-
tem SPSS version 12.0 (SPSS Inc., Chicago, IL, USA). Sample
size was estimated using the total blood loss as the primary
variable with a hypothesis of its decrease by 50%, so a group
size of 25 patients was found sufﬁcient to achieve 90% power.
Descriptive data are expressed as mean (±SD), and was com-
pared using unpaired t-test, X2 test, Wilcoxon rank sum test,
and Fisher exact test as appropriate. A P-value less than
0.05 was considered statistically signiﬁcant (see Fig. 1).
3. Results
The current study showed no signiﬁcant differences in demo-
graphic data including age, sex, body weight or height between
group A and group T as shown in Table 1, furthermore, the
difference in the duration of surgical procedures between both
groups was nonsigniﬁcant, group A 269 ± 25 min and group
T 273 ± 29 min (Table 1).
The total perioperative blood loss (primary outcome) in
group A was (1630 ± 495), which was signiﬁcantly lower than
group T (1970 ± 530) as indicated in Fig. 2, furthermore, the
total volume of transfused blood intraoperatively (secondary
outcome) showed a signiﬁcantly higher result in group T
(1349 ± 53) compared to group A (989 ± 49) as shown in
Fig. 2 with P< 0.05.
Neither of the patients of the present study required ICU
admission; all patients were shifted to the post-anesthesia care
unit (PACU) then back to their units, furthermore, none of the
patients needed reentry to operating theater. Besides, no
patients in both groups developed postoperative adverse
effects including bleeding or thrombo-embolic complications
as shown in Table 2. No signiﬁcant difference was detected
in the number of patients needed blood transfusion between
the groups of the present study as indicated in Table 2. As
regards the total perioperative IV ﬂuid infusion, intraopera-
tively colloid consumption for group A was slightly lower than
group T with P= 0.81 with no signiﬁcant difference, while
crystalloid consumption was comparatively lower in group A
with P= 0.12. On the other hand, postoperatively, group TGroup A 
(n =25) 
Received Acvated 
recombinant VII (n=25)
Sampled for primary & secondary 
outcomes (n=25)
Assessed fo
and randomiz
Figure 1 The patient selection, alloshowed insigniﬁcantly higher infusion of both colloids as well
as crystalloids with P= 0.55 and P= 0.61 respectively as
shown in Table 2.
Regarding the hemoglobin level, intraoperative bleeding
was associated with a slight decrease of hemoglobin in group
A that improved postoperatively following blood transfusionGroup T 
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Received Tranexamic 
acid (n=25)
Sampled for primary & secondary 
outcomes (n=25)
r eligibility 
aon (n=50) 
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Table 2 Secondary outcome variables data. Values are expressed as mean ± SD.
Group A Group T
(n= 25) (n= 25)
Patients who needed blood transfusion 15(60%) 18(72%)
Need for ICU admission 0 0
Need for reentry to OR 0 0
Total colloid infusion (ml)
Intraoperative 980 ± 30 1076 ± 28
Postoperative 469 ± 50 474 ± 30
Total crystalloid infusion (ml)
Intraoperative 2690 ± 25 2710 ± 29
Postoperative 1060 ± 110 1080 ± 130
Incidence of postoperative adverse eﬀects 0 0
No signiﬁcant differences between the two groups. (P value > 0.05).
152 H.A. ELShamaa, S.A. ELokdawhich was not signiﬁcantly different from group T as seen in
Fig. 3, moreover, the coagulation parameters (PT, INR, and
aPTT) in both groups were normal before the start of surgery.
In group T it remained within normal preoperative ranges all
through the study duration, both intraoperative and postoper-
ative, nevertheless, group A showed shortening of PT
(10.3 ± 0.4 s), aPTT (28 ± 1.7 s) and decrease of INR
(0.8 ± 0.3) intraoperatively after recombinant factor VII injec-
tion which returned to initial value after 24 h postoperatively,
however, both groups showed no signiﬁcant difference among
their patients.
4. Discussion
In the present study, it was found that the adminstration of
100 lg/kg activated recombinant factor VII during major sur-
gical procedure as spine surgery, signiﬁcantly decreased the
blood loss both intraoperatively as well as postoperatively
compared with tranexamic acid, furthermore, its use minimizes
the total volume of intraoperative transfusion of blood and its
products. In addition, the coagulation parameters evaluated in
the present study including PT, INR, and aPTT were short-
ened after Recombinant factor VII administration compared
to the tranexamic acid that showed no effect on these param-
eters, however, no postoperative complications especially
thrombo-embolic events or major bleeding was reported, and
none of the studied patient needed ICU admission.0
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Figure 3 The hemoglobin concentration intra and postoperative.
No signiﬁcant difference (P> 0.05).The utilization of activated recombinant factor VII for
management of bleeding in non-hemophilic patients is increas-
ing progressively [11]. Previous published studies in literature
reported that the use of activated recombinant factor VII,
showed hemostatic efﬁcacy in patients with impaired haemo-
stasis such as hemophilia A or B [12]. This was owing to the
formation of a complex with tissue factor (TF), which is a
membrane bound glycoprotein, available in the wound bed.
This glycoprotein (TF) is present in the subendothelial cells
which are separated from the blood stream, upon injury (trau-
matic or surgical) it becomes exposed to the blood stream due
to disruption of the cell membrane [13]. Due to its afﬁnity, TF
binds to recombinant factor VII resulting in activation of fac-
tor X to Xa of coagulation factors resulting in generation of
thrombin and subsequently the formation of ﬁbrin, further-
more, ﬁbrin activates other coagulation factors e.g. factors
V, VIII, hence facilitating hemostasis [14].
Supporting the results of the present study were the results
of the double blinded randomized study done by Friederich
et al. [15], who studied the effect of activated recombinant fac-
tor VII on the perioperative blood loss in abdominal prostatec-
tomy compared to placebo and concluded that its use in a dose
of 40 lg/kg in the early phase of the surgical procedure
improves hemostasis and minimizes blood loss, hence
decreases the need for blood transfusion, suggesting that the
use of higher doses may be more beneﬁcial. In addition, in a
study by Diprose et al. [16] assessing the effect of activated
recombinant factor VII in non coronary cardiac surgery and
the need of transfusion after the cardiopulmonary bypass,
the authors concluded that administrating recombinant factor
VII was beneﬁcial and reduced the need for blood transfusion
in such patients without causing any side effects. Moreover,
Liu and colleagues [17] studied the value of recombinant factor
VII in patients for intracerebral hematoma drainage having
factor VII deﬁciency and found out that its use was effective
in emergency neurosurgery. On the contrary, in a study by
Bowels and colleagues [18] for predicting the response of
non-hemophilic patients with bleeding to activated recombi-
nant factor VII, they showed that only eight patients
responded to an early single dose of factor VII who had good
prognosis while patients with poor prognosis showed no
response suggesting that its efﬁcacy depending on the time of
administration that may affect the prognosis. This may prob-
ably be explained in the present study by our use of activated
recombinant factor VII as an early prophylaxis before the
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et al. [19], the authors studied the effect of activated recombi-
nant factor VII on bleeding in patients undergoing surgery for
traumatic pelvic fracture, and their results demonstrated that
the prophylactic administration of recombinant factor VIIa
in such patient does not reduce the intraoperative bleeding
or minimize the perioperative blood loss. Compared to our
study these results may be explained by the higher dose of fac-
tor VII used in the present study, besides the longer postoper-
ative duration of their study may add to the total blood loss.
Going with the result of this study were the results of the
study done by Good and colleagues [20] who showed that tran-
examic acid may decrease the blood loss through reducing
drained blood, yet it had minimal effect on concealed blood
and hence the total blood loss. Whereas, many other studies
concluded the beneﬁcial effect of tranexamic acid on intraop-
erative bleeding.
In conclusion, the present study demonstrated that prophy-
lactic administration of activated recombinant factor VII in
spine surgery reduces the total perioperative blood loss and
the total volume of intraoperative blood transfusion compared
with tranexamic acid, with no evidence of side effects or ICU
admission. However, further studies are required to assess the
efﬁcacy of various doses of activated recombinant factor VII,
and to compare it with other antiﬁbrinolytic agents, in addi-
tion to evaluation of its beneﬁts against the risk of developing
hypercoagulable state or thrombo-embolic complications.
Conﬂict of interest
No conﬂict of interest to declare.
References
[1] Prentice CR. Basis of antiﬁbrinolytic therapy. J Clin Pathol
Suppl (R Coll Pathol) 1980;14:35–40.
[2] Mannucci PM. Hemostatic drugs. N Engl J Med
1998;339(4):245–53.
[3] Mannucci PM, Levi M. Prevention and treatment of major
blood loss. N Engl J Med 2007;356:2301–11.
[4] Zufferey P, Merquiol F, Laporte S, et al. Do antiﬁbrinolytics
reduce allogenic blood transfusion in orthopedic surgery?
Anesthesiology 2006;105:1034–46.
[5] Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic
acid reduces blood loss and blood transfusion after knee
arthroplasty; a prospective randomized double blinded study. J
Bone Joint Surg 1996;78-B:434–40.
[6] Pychynska PM, Moll JJ, Krajewski W, et al. The use of
recombinant coagulation factor VII in uncontrolledpostoperative bleeding in children undergoing cardiac surgery
with cardiopulmonary bypass. Pediatr Crit Care Med
2004;5:246–50.
[7] Hendriks HG, Meijer K, De wolf JT, et al. Reduced transfusion
requirements by recombinant factor VII in orthotopic liver
transplantation; a pilot study. Transplantation 2001;71:402–5.
[8] Serena SH. Blood loss in adult spinal surgery. Eur Spine J
2004;13(suppl. 1):S3–5.
[9] Farrokhi MR, Kazemi AP, Akbari K, et al. Efﬁcacy of
prophylactic low dose of tranexamic acid in spinal ﬁxation
surgery: a randomized clinical trial. J Neurosurg Anesthesiol
2011;10(4):290–6.
[10] Jansen AJ, Andreica S, Claeys M, et al. Use of tranexamic acid
for an effective blood conservation strategy after total knee
arthroplasty. BJA 1999;83:596–601.
[11] MacLaren R, Weber LA, Brake H, et al. A multicenter
assessment of recombinant factor VIIa off-label usage; clinical
experiences and associated outcomes. Transfusion
2005;45:1434–42.
[12] Slappendel R, Huvers FS, Benraad B, et al. Use of recombinant
factor VIIa (NovoSeven) to reduce postoperative bleeding after
total hip arthroplasty in patient with cirrhosis and
thrombocytopenia. Anesthesiology 2002;96:1525–7.
[13] Tobias JD. Synthetic factor VIIa to treat dilutional
coagulopathy during posterior spinal fusion in two children.
Anesthesiology 2002;96:1522–5.
[14] Rodriguez EC, Weidel JD, Wallny T, et al. Elective orthopedic
surgery for inhibitor patient. Hemophilia 2003;9:625–30.
[15] Friederich PW, Henny CP, Messelink EJ, et al. Effect of
recombinant activated factor VII on perioperative blood loss
in patients undergoing retropubic prostatectomy; a double
blinded placebo controlled randomized trial. Lancet
2003;361:201–5.
[16] Diprose P, Herberston MJ, Gill RS, et al. Activated
recombinant factor VII after cardiopulmonary bypass reduces
allogenic transfusion in complex non-coronary cardiac surgery:
randomized double blinded placebo controlled pilot study. BJA
2005;95(5):596–602.
[17] Liu N, Aldea S, Francois D, et al. Recombinant activated factor
VII for a patient with factor VII deﬁciency undergoing urgent
intracerebral hematoma evacuation with underlying cavernous
angioma. BJA 2009;103(6):858–60.
[18] Bowels KM, Callaghan CJ, Taylor AL, et al. Predicting
response to recombinant factor VIIa in non-hemophilic
patients with severe hemorrhage. BJA 2006;97(4):476–81.
[19] Raobaikady R, Redman J, Ball AS, et al. Use of activated
recombinant coagulation factor VII in patients undergoing
reconstruction surgery for traumatic fracture of pelvis or pelvis
and acetabulum: a double blinded randomized placebo
controlled trial. BJA 2005;94(5):586–91.
[20] Good L, Peterson E, Lisander B. Tranexamic acid decreases
external blood loss but not hidden blood loss in total knee
replacement. BJA 2003;90(5):596–9.
